Drug intelligence / Profile preview

FCN-647

Development stage: Unknown
Lead developer: Fochon Biosciences
Modality: Small Molecules

Overview

FCN-647 is a selective and potent small-molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Chongqing Fochon Pharmaceutical. BTK is a critical component of the B-cell receptor (BCR) signaling pathway, which is essential for the survival and proliferation of malignant B-cells. By inhibiting BTK, FCN-647 aims to treat various B-cell malignancies, including lymphoma, chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. The drug is currently in Phase 1 clinical development.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on FCN-647.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCN-647.

Explore the full profile